 |
|
|
|
|
 |
Last Updated: Nov 1, 2009 - 11:48:48 PM |
Latest Research
:
Cardiology
Anemia linked with higher death risk in heart patients
The presence of anaemia in patients with chronic heart failure is linked to a significantly higher risk of death.
Jun 18, 2009 - 3:42:04 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Deferasirox
Deferasirox may revolutionize the way chronic iron overload is treated
Those with severe chronic anemias need frequent blood transfusions to remain healthy, but such frequent transfusions can cause a potentially deadly buildup of iron in the body, leading to heart and liver failure. The traditional treatment to remove excess iron is so onerous that many patients choose to forgo it, putting their own lives at risk. The results of an international study on deferasirox, a new drug that may revolutionize the way chronic iron overload is treated, will be published in the May 1, 2006, issue of Blood, the official journal of the American Society of Hematology.
Apr 23, 2006 - 6:22:37 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
FDA approves extended dosing of Aranesp
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp® (darbepoetin alfa) for the treatment of chemotherapy-induced anemia (low red blood cell count) in patients with non-myeloid malignancies. Aranesp is the only erythropoiesis-stimulating agent approved by the FDA for every-three-week administration.
Mar 28, 2006 - 7:58:37 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Study Suggests Drug For Chemotherapy-Induced Anemia Can Be Effectively Administered Tri-Weekly
Parallel administration of chemotherapy and an anti-anemia drug called darbepoetin alfa every 3 weeks is safe and effective, according to a new study.
Feb 15, 2006 - 8:00:37 PM
|
Latest Research
:
Haematology
:
Anaemia
Aranesp treatment achieved and maintained target hemoglobin levels and reduced incidence of red blood cell transfusions
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced interim results from the first multi-center, randomized, double-blind, placebo-controlled, Phase 3 trial of Aranesp® (darbepoetin alfa) administered every three weeks in cancer patients with chemotherapy-induced anemia. The study revealed that Aranesp increased and maintained patient hemoglobin levels to the target level of greater than or equal to 11 grams per deciliter (g/dL) and reduced the need for red blood cell transfusions by almost half compared to placebo. The data were presented at the American Society of Hematology (ASH) 47th Annual Meeting and Exposition. (Abstract #3556)
Dec 14, 2005 - 8:08:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Interim Aranesp data suggest major response in anemic patients with MDS
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp darbepoetin alfa) administered every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndrome (MDS). Low-risk MDS patients receiving Aranesp every three weeks, who had no prior erythropoietic therapy, exhibited an overall response of 70 percent, increased hemoglobin levels and improvements in patient-reported fatigue.
Dec 13, 2005 - 8:05:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Interim data suggest major response with Aranesp(R) in anemic patients with MDS
Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today announced new interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa) every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndromes (MDS). The data were presented at the 17th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC) in Geneva. (Abstract #02-007)
Jul 10, 2005 - 8:16:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Aranesp dosed every three weeks achieved and maintained target hemoglobin levels
Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients receiving chemotherapy demonstrated that Aranesp® (darbepoetin alfa) administered every three weeks was effective in increasing and maintaining patient hemoglobin levels to the recommended target of greater than or equal to 11 g/dL. Further, treatment with Aranesp reduced the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia.
May 16, 2005 - 8:26:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Final results demonstrate Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly
Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that 200 mcg of Aranesp® (darbepoetin alfa) administered every two weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia.
May 16, 2005 - 8:22:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Anemia drug reduces transfusions and chemotherapy-related fatigue
Patients treated with darbepoetin alfa (AranespTM) for chemotherapy-induced anemia may require fewer blood transfusions and feel less fatigued than patients receiving a placebo, concludes a new study in the August 21 issue of the Journal of the National Cancer Institute.
Aug 28, 2002 - 8:14:38 PM
|
<< prev
next >>
|
|
|
|
